Skip to search formSkip to main contentSkip to account menu

darapladib

A substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2), an important regulator of lipid… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
© 2018 Titin Andri Wihastuti et al. This is an open access article distributed under the terms of the Creative Commons… 
2016
2016
Background: Atherosclerosis is a chronic inflammation disease that is caused by the interaction between monocyte and endothelial… 
2016
2016
Atherosclerosis is a chronic inflammation response of cholesterol deposition in artery vascular wall. The most common risk factor… 
2014
2014
The absorption, metabolism, and excretion of darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2, was… 
2014
2014
Background Elevated lipoprotein-associated phospholipase A 2 activity promotes the development of vulnerable atherosclerotic… 
2013
2013
Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is involved in the pathogenesis of atherosclerosis, especially in… 
Review
2013
Review
2013
Inflammation plays an important role in origin and progression of atheromatous plaque. Lipoprotein-associated phospholipase A2… 
Review
2012
Review
2012
Certain members of the phospholipase A2 superfamily of enzymes have established causal involvement in atherosclerosis, thus at… 
2010
2010
Abstract Darapladib is a novel oral compound that selectively inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2…